Quantitative tl spet imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?

Nuclear Medicine Communications

Volumn 21, Issue 3, 2000, Pages 259-267

  KALLEN K ^a   Geijer, B ^a   MalmstrOm P ^a   Andersson, A M ^a   HoltAs S ^a   Ryding, E ^a   RosEn I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; LOMUSTINE; PCV PROTOCOL; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; THALLIUM; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; TIME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THALLIUM RADIOISOTOPES; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VINCRISTINE;

EID: 0034150758     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200003000-00010     Document Type: Article

References (36)

1. Perry JR, DeAngelis LM, Schold Jr SC et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997; 49: 912-917.
2. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definitions for response and relapse in children with brain tumors. Cancer 1985; 56: 1824-1826.
3. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
4. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-364.
5. Grant R, Slattery J, Gregor A, Whittle IR. Recording neurological impairment in clinical trials of glioma. J Neurooncol 1994; 19: 37-49.
6. Murovic J, Turowski K, Wilson CB, Hoshino T, Levin V. Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg 1986; 65: 799-806.
7. Cairncross JG, Pexman JH, Rathbone MP, DelMaestro RF. Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 1985; 17: 570-572.
8. Peterson K, Clark HB, Hall WA, Truwit CL. Multifocal enhancing magnetic resonance imaging lesions following cranial irradiation. Ann Neurol 1995; 38: 237-244.
9. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. Radiology 1986; 158: 149-155.
10. Fine HA. Novel biologic therapies for malignant gliomas: Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin 1995; 13: 827-846.
11. Sandberg-Wollheim M, Malmstrom P, Stromblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: 22-29.
12. Stenning SP, Freedman LS, Bleehen NM. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 1987; 56: 89-90.
13. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988; 68: 1-17.
14. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597.
15. Chandler KL, Prados MD, Malec M, Wilson CB. Long-term survival in patients with glioblastoma multiforme. Neurosurgery 1993; 32: 716-720.
16. Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990; 18: 321-324.
17. Tonami N. Thallium-201 SPECT in the evaluation of gliomas. J Nucl Med 1993; 34: 2089-2090.
18. Yoshii Y, Satou M, Yamamoto T et al. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. Eur J Nucl Med 1993; 20: 39-45.
19. Carvalho PA, Schwartz RB, Alexander III E et al. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992; 77: 565-570.
20. Mountz JM, Stafford-Schuck K, McKeever PE, Taren J, Beierwaltes WH. Thallium-201 tumor/cardiac ratio estimation of residual astrocytoma. J Neurosurg 1988; 68: 705-709.
21. Zhang JJ, Park CH, Kim SM, Ayyangar KM, Haghbin M. Dual isotope SPECT in the evaluation of recurrent brain tumor. Clin Nucl Med 1992; 17: 663-664.
22. Schwartz RB, Carvalho PA, Alexander III E, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma: Differentiation by using dual-isotope SPECT with 201Tl and 99mTc-HMPAO. Am J Neuroradiol 1991; 12: 1187-1192.
23. Slizofski WJ, Krishna L, Katsetos CD et al. Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. Cancer 1994; 74: 3190-3197.
24. Abdel-Dayem H. 201Tl-chloride uptake ratios in differentiating benign from malignant lesions: Recommendations for ratio calculations and interpretation. Nucl Med Commun 1995; 16: 145-149.
25. Rodrigues M, Fonseca AT, Salgado D, Vieira MR. 99Tcm-HMPAO brain SPECT in the evaluation of prognosis after surgical resection of astrocytoma: Comparison with other noninvasive imaging techniques (CT, MRI and 201Tl SPECT). Nucl Med Commun 1993; 14: 1050-1060.
26. Oriuchi N, Tamura M, Shibazaki T et al. Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: Relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 1993; 34: 2085-2089.
27. Mountz JM, Duetsch G, Kuzniecky R, Rosenfeld SS. Brain SPECT. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press, 1994: 48-49.
28. 201Tl SPET tumour uptake volume. Nucl Med Commun 1999; 20: 837-844.
29. Kernohan JW, Mabon RF, Svein HJ, Adson AW. A simplified classification of gliomas. Proc Staff Meet Mayo Clinic 1949; 24: 71-75.
30. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology 1995; 45: 929-933.
31. Meckling S, Dold O, Forsyth PA, Brasher P, Hagen NA. Malignant supratentorial glioma in the elderly: Is radiotherapy useful? Neurology 1996; 47: 901-905.
32. Lesser GJ, Grossman SA. The chemotherapy of adult primary brain tumors. Cancer Treat Rev 1993; 19: 261-281.
33. Kim KT, Black KL, Marciano D et al. Thallium-201 SPECT imaging of brain tumors: Methods and results. J Nucl Med 1990; 31: 965-969.
34. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997; 48: 1336-1340.
35. Källén K, Heiling M, Andersson A-M, Brun A, Holtås S, Ryding E. Preoperative grading of glioma malignancy with thallium-201 single-photon emission CT: Comparison with conventional CT. Am J Neuroradiol 1996; 17: 925-932.
36. Butler AR, Horii SC, Kricheff II, Shannon MB, Budzilovich GN. Computed tomography in astrocytomas: A statistical analysis of the parameters of malignancy and the positive contrast-enhanced CT scan. Radiology 1978; 129: 433-439.